< 回列表
陶运淦
- Chief Radiation Oncologist in Head and neck/Skin/endocrinology cancers in Institut Gustave Roussy, Villejuif, Grand Paris, France
- Chairman-Elect of French head and neck oncology and radiotherapy group (GORTEC)
GORTEC experiences in clinical research of Head and Neck cancers
| 角色 | 講師 |
| 日期時間 | 05/02 10:00 - 10:50 |
| 地點 | 701C |
學歷 / 訓練
1997
MD
Shanghai medical university (Now Fudan university), China
2002
OTHERS
University Paris VI, France
2008
PhD
University Paris VI, France
專業與研究經歷
1997
- 2002
Shanghai Cancer hospital (now Fudan university cancer centre), China
2002
- 2004
Institut Gustave Roussy, France
2007
- 2011
Institut Gustave Roussy, France
2011
- Present
Institut Gustave Roussy, France
2024
- Present
GORTEC, France
重要出版品
- Bourhis J, Aupérin A, Borel C, … Tao Y. Nivolumab added to cisplatin-radiotherapy versus cisplatin-radiotherapy alone after surgery for patients with squamous cell carcinoma of the head and neck at high-risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial. Lancet 2025 Dec. 22, DOI: 10.1016/S0140-6736(25)01850-1. Online ahead of print. (Corresponding author)
- Uppaluri R, Haddad RI, Tao Y, et al. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. N Engl J Med. 2025 Jul 3;393(1):37-50. doi: 10.1056/NEJMoa2415434. Epub 2025 Jun 18.
- Tao Y, Biau J, Sun XS, et al. Pembrolizumab versus cetuximab, concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit to cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase 2 trial. Ann Oncol. 2023 Jan;34(1):101-110. doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28.
- Sun XS, Tao Y, Le Tourneau C, et al. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Lancet Oncol. 2020 Sep;21(9):1173-1187. doi: 10.1016/S1470-2045(20)30327-2. Epub 2020 Aug 3.PMID: 32758455 (Co-first author)
- Tao Y, Auperin A, Sire C, et al. Improved outcome by adding concurrent chemotherapy to cetuximab-radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007-01 phase III randomized trial. J Clin Oncol. 2018 Jun 7:JCO2017762518. doi: 10.1200/JCO.2017.76.2518. [Epub ahead of print]